Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

摘要

The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

主权项

1. A method of treating a cancer characterized by cells expressing claudin 18 splice variant 2, comprising:
administering to a patient an antibody having the ability of binding to claudin 18 splice variant 2 (CLDN18.2) in combination with an agent stimulating γδ T cells and an agent stabilizing or increasing expression of CLDN18.2, wherein the agent stimulating γδ T cells is a bisphosphonate and the agent stabilizing or increasing expression of CLDN18.2 comprises at least one anthracycline, at least one platinum compound and at least one of 5-fluorouracil and prodrugs thereof.